Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial

Please use this identifier to cite or link to this item: https://islhd.intersearch.com.au/islhdjspui/handle/1/6723

Title:	Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
ISLHD Author:	Zebic, Danka S
Authors:	Sjoquist KM;Dobrovic A;Robledo KP;Nesic K;Baron-Hay S;Ananda S;McCarthy N;Goh J;Steer C;Murray N;Yip S;Mileshkin LR;Fink JL;Chang G;Bailey L;Lee Y;Zebic DS;Kariyawasam UGIU;Shield-Artin K;Jarratt A;Bedő J;Papenfuss AT;Kondrashova O;Wakefield MJ;Vandenberg CJ;Stockler MR;Scott CL;Waring PM
Keywords:	Breast Cancer;Ovarian Cancer
Date Published:	1-Oct-2026
Citation:	Br J Cancer. 2026 Oct;135(7):1152-1163. doi: 10.1038/s41416-026-03535-6. Epub 2026 Jul 8.
URI:	https://islhd.intersearch.com.au/islhdjspui/handle/1/6723
DOI:	10.1038/s41416-026-03535-6
Journal Title:	Br J Cancer
Appears in Collections:	Research publications from current and former ISLHD staff.

Files in This Item:

There are no files associated with this item.